Caveat Against the Use of Activated Recombinant Factor VII for Intractable Bleeding in Cardiac Surgery
- 1 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 94 (5) , 1369-1370
- https://doi.org/10.1097/00000539-200205000-00070
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VIIAnesthesia & Analgesia, 2001
- Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human SubjectsCirculation, 2001
- Update on the Management of Acute Coronary SyndromesCardiology, 2000
- AprotininDrugs, 1999
- Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and InhibitorThrombosis and Haemostasis, 1999
- Direct activation of factor X by monocytes occurs during cardiopulmonary bypassBritish Journal of Haematology, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: A clinical studyThe Journal of Thoracic and Cardiovascular Surgery, 1997